Task B2 · evidence aggregation
According to the corpus, what class of drug exploits homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers, and what is the general premise of this therapeutic approach?
Gold evidence
Acceptable answer concepts
- PARP inhibitors
- homologous recombination deficiency
- ovarian and breast cancers
- precision oncology
Construction note
Concepts taken verbatim from PMID:42648415's abstract ('Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized... precision oncology, particularly in tumors harboring homologous recombination deficiency (HRD), such as ovarian and breast cancers').
How each architecture answered
Baseline 0 · no retrieval
Yuu no Sekai · 595 tokens · 4.9sBased on general biomedical knowledge, PARP inhibitors are a class of drugs that exploit homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers. The general premise of this therapeutic approach is that cancer cells with HRD, such as those with BRCA mutations, are more susceptible to PARP inhibitor treatment because these inhibitors prevent the repair of single-strand DNA breaks, leading to accumulation of double-strand breaks and ultimately cell death.
PARP inhibitors are a class of drugs that exploit homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers.
The general premise of using PARP inhibitors in HRD cancers is that these inhibitors prevent the repair of single-strand DNA breaks, leading to accumulation of double-strand breaks and ultimately cell death.
Baseline 1 · retrieve + synthesize
Yuu no Sekai · 2992 tokens · 5.5sPARP inhibitors (PARPi) exploit homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers. The general premise of this therapeutic approach is that HRD leads to defective DNA repair, making cancer cells more susceptible to PARP inhibitors which further impair their ability to repair DNA damage.
PARP inhibitors (PARPi) exploit homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers.
The general premise of the therapeutic approach using PARP inhibitors is that HRD leads to defective DNA repair, making cancer cells more susceptible to PARP inhibitors which further impair their ability to repair DNA damage.
Agent 1 · planner + retrieve + synthesize
Yuu no Sekai · 3215 tokens · 7.7sThe class of drug that exploits homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers is poly(ADP-ribose) polymerase (PARP) inhibitors. The general premise of this therapeutic approach is that HRD leads to impaired DNA repair, making cancer cells more sensitive to PARP inhibitors, which further disrupts DNA repair mechanisms.
Poly(ADP-ribose) polymerase (PARP) inhibitors exploit homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers.
The general premise of exploiting HRD in BRCA-associated cancers involves the use of PARP inhibitors to further impair DNA repair mechanisms in cancer cells.